An open label, Phase 1/2 study of miransertib administered to subjects at least 2 years of age with PROS and Proteus syndrome (PS) is currently underway to more accurately assess the efficacy of miransertib in the treatment of PIK3CA-related overgrowth spectrum disorder [21]. The gene discussed is PIK3CA; the disease is Proteus syndrome.